Skip to main content
Lotus Pharm logo

Lotus Pharm — Investor Relations & Filings

Ticker · 1795 ISIN · TW0001795003 LEI · 984500BEECDBC04KP716 TW Manufacturing
Open in API
Filings indexed 2,730 across all filing types
Latest filing 2024-06-12 Investor Presentation
Country TW Taiwan
Listing TW 1795

About Lotus Pharm

http://www.lotuspharm.com.tw

Lotus Pharmaceutical Co., Ltd. is a global specialty organization focused on the development, manufacturing, and commercialization of high-barrier generic and specialty medicines. The company specializes in complex generics, with a primary focus on oncology, immunology, and addiction treatment. Its portfolio includes technically demanding products such as Lenalidomide, Suboxone, Nintedanib, and Vinorelbine, as well as an advancing pipeline of biosimilars and 505(b)(2) oncology candidates. Utilizing an integrated R&D and manufacturing platform, the company executes a "2x2" growth strategy centered on dual market expansion and product diversification. Its commercial footprint spans over 90 markets globally, maintaining a strong presence in the Asia-Pacific region and the United States. The company prioritizes high technical entry barriers and cost-effective therapeutic solutions to improve global patient access to essential medications.

Recent filings

Filing Released Lang Actions
113年06月法人說明會簡報 — 179520240612M001.pdf
Investor Presentation Classification · 95% confidence The document is a detailed corporate presentation about 美時製藥公司 (a pharmaceutical company), dated June 2024. It includes forward-looking statements, company milestones, management team bios, business strategy, product pipeline, market segmentation, and recent operational highlights. The content is structured as a presentation with slides, charts, and pictures, focusing on company growth, strategy, and financial metrics like revenue and EPS growth. There is no indication that this is a formal regulatory filing such as an annual report (10-K), quarterly report (IR), or earnings release (ER). It is not an announcement of a report publication either, as it contains substantive business and financial information. The nature of the document aligns with an Investor Presentation (IP), which typically includes forward-looking statements, strategic overview, management profiles, and financial highlights for investors. Therefore, the best classification is Investor Presentation (IP).
2024-06-12 Chinese
113年06月法人說明會簡報 — 179520240607E001.pdf
Investor Presentation Classification · 95% confidence The document is a detailed presentation from Lotus Pharmaceutical dated June 2024. It contains forward-looking statements, company milestones, revenue and EPS historical data, management team details, business strategy, product portfolio, R&D pipeline, and near-term business highlights. The content is structured as a comprehensive overview of the company's financials, strategy, and market position aimed at investors. There is no indication that this is an official annual report or regulatory filing, nor is it a transcript or earnings release. The presence of slides, forward-looking statements, and strategic information strongly suggests this is an Investor Presentation (IP). The document length (10,491 characters) and detailed content support this classification rather than a brief announcement or report publication notice.
2024-06-12 Chinese
113年06月法人說明會簡報 — 179520240607M001.pdf
Investor Presentation Classification · 95% confidence The document is a detailed corporate presentation about 美時製藥公司 (a pharmaceutical company), dated June 2024. It includes forward-looking statements, company milestones, management team bios, business strategy, product pipeline, market segmentation, and recent operational highlights. The content is structured as a presentation with slides containing charts, pictures, and text describing the company's growth, strategy, and financial metrics such as revenue and EPS growth. There is no indication that this is a formal regulatory filing like an Annual Report (10-K) or Interim Report (IR), nor is it a brief announcement or certification. The document is clearly designed for investors and stakeholders to understand the company's financial position, strategy, and outlook, which fits the definition of an Investor Presentation (IP). The length (7,938 characters) and detailed content support this classification. Therefore, the filing type is Investor Presentation (IP) with high confidence.
2024-06-12 Chinese
113年06月法人說明會簡報
Investor Presentation Classification · 95% confidence The document is a listing of scheduled investor presentations (法人說明會) with dates, times, locations, and links to presentation materials (PDFs). It includes descriptions such as '說明本公司之營運概況、財務及業務相關資訊' which translates to explaining the company's operational overview, financials, and business information. This matches the definition of an Investor Presentation (IP). The document length is short and it is not a report itself but a schedule and summary of presentations. However, since it contains direct links to presentation materials and detailed descriptions of the presentations, it is best classified as Investor Presentation (IP) rather than a mere announcement (RPA).
2024-06-12 Chinese
113年06月法人說明會簡報 — 179520240624E001.pdf
Investor Presentation Classification · 95% confidence The document is a detailed presentation from Lotus Pharmaceutical dated June 2024. It contains extensive information about the company's business strategy, management team, product portfolio, market expansion, revenue and EPS trends over multiple years, R&D pipeline, and commercial infrastructure. The content is forward-looking and strategic, with charts and data supporting growth plans and market positioning. There are no indications that this is a regulatory filing, audit report, earnings release, or annual/interim financial report. The document is clearly designed for investors and stakeholders to understand the company's financials, strategy, and market position. This matches the definition of an Investor Presentation (IP). The document length (over 12,000 characters) and detailed content confirm it is the presentation itself, not just an announcement or summary. Therefore, the correct classification is Investor Presentation (IP) with high confidence.
2024-06-07 Chinese
113年06月法人說明會簡報 — 179520240624M001.pdf
Investor Presentation Classification · 95% confidence The document is a detailed corporate presentation about 美時製藥公司 (a pharmaceutical company), including company overview, growth milestones, management team, business strategy, product pipeline, market segmentation, and recent operational highlights. It contains forward-looking statements, financial growth data, and strategic plans. The content is structured as a presentation with slides and pictures, focusing on financials, strategy, market position, and management profiles. There is no indication that this is an official annual report, earnings release, or regulatory filing. It is not a transcript of a call, nor an audit or legal report. The document is consistent with an investor presentation, which typically includes forward-looking statements, company milestones, management bios, and strategic outlook. Therefore, the most appropriate classification is Investor Presentation (IP).
2024-06-07 Chinese

Browse filings by year

14 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.